Overview

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Status:
Completed

Trial end date:
2011-04-18

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder (MDD) as measured by the Global Executive Composite (GEC) T-score of the Behavioral Rating Inventory of Executive Functioning - Adult Version (BRIEF-A).

Phase:

Phase 2

Details

Lead Sponsor:

Shire

Treatments:

Lisdexamfetamine Dimesylate